Adjuvant hormonotherapy in breast cancer - is “the option zero” realistic?

Krzysztof Krzemieniecki, Marek Pawlicki
Oncol Clin Pract 2005;1(4):192-200.

open access

Vol 1, No 4 (2005)
REVIEW ARTICLES
Published online: 2005-12-12

Abstract

Adjuvant hormonal therapy increases disease free interval and overall survival, reduces risk of distant metastases and second breast cancer in patients with hormone-sensitive early breast cancer.
Documented clinical advantage of aromatase inhibitors led to numerous trials on the use of this class of agents in the adjuvant setting for postmenopausal women. Based on the results of these trials sufficient data exist to consider sequential hormonotherapy, although there are still some not resolved elements of this strategy. Primary adjuvant hormonotherapy with aromatase inhibitors seems to be limited to patients in whom tamoxifen is contraindicated or not tolerated. Expert panels advise to be cautious and potential guidelines modifications should be based on the final results of current studies with clarification of all controversial issues.
At present, the results of several studies on the use of hormonal adjuvant therapy in premenopausal women are available and they give some evidence to switch for hormonal therapy and gonadoliberin analogues in the adjuvant setting. More data are necessary to establish optimal time framework for adjuvant hormonotherapy.
Launching new drugs in adjuvant breast cancer therapy may require revision of current treatment guidance. The future adjuvant therapy may be much more tailored based on individual genetic profile derived from microarrays study.

Keywords

hormonosensitive breast cancer; adjuvant treatment; aromatase inhibitors; LHRH analogues

About this article
Title

Adjuvant hormonotherapy in breast cancer - is “the option zero” realistic?

Journal

Oncology in Clinical Practice

Issue

Vol 1, No 4 (2005)

Pages

192-200

Published online

2005-12-12

Bibliographic record

Oncol Clin Pract 2005;1(4):192-200.

Keywords

hormonosensitive breast cancer
adjuvant treatment
aromatase inhibitors
LHRH analogues

Authors

Krzysztof Krzemieniecki
Marek Pawlicki

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl